Special Issues

Special Issue Title: Cardiac Hypertrophy: from Basic Science to Clinical Application

· Print Special Issue Flyer

· Deadline for manuscript submissions: 31 March 2022


Special Issue Editor

Guest Editor


Prof. Dr. Zoltán Papp

Department of Cardiology, Division of Clinical Physiology, Faculty of Medicine, University of Debrecen, Hungary

Website | E-Mail

Interests: Animal physiology; Signaling pathways; Cardiac function; Physiology; Isolated cardiomyocyte studies; Cardiomyocyte mechanics; Patch-clamp Electrophysiology; Cell signaling; Phosphorylation; Heart failure; Positive inotropic agents



Dr. Attila Kiss

Center for Biomedical Research, Medical University of Vienna, Austria

Website | E-Mail

Interests: Cardioprotection in chronic and acute myocardial ischemia/reperfusion; Mechanism of left ventricular remodeling in cardiovascular disease


Special Issue Information

Dear Colleagues,


Indices of myocardial morphology and function should fall within physiological ranges at both the macroscopic and microscopic levels for stable cardiac performance. Accordingly, cardiac chamber sizes together with the characteristics of cardiomyocytes and their subcellular micro-organelles are to be analyzed in combination for the correct interpretation of cardiac health and disease.
Upon various different stress conditions (i.e. hemodynamic pressure- or volume-overload, genetic predispositions, etc.) cardiac muscle enters a transformation process, commonly referred to as cardiac hypertrophy. Thickening of the heart muscle often appears as a compensatory mechanism, nevertheless, concomitant alterations in cardiomyocyte signaling can also limit systolic and/or diastolic functions and evoke life-threatening arrhythmias. In this context, concentric left ventricular hypertrophy has been mostly associated with diastolic dysfunction, leading potentially to heart failure with preserved ejection fraction (HFpEF), while heart failure with reduced ejection fraction (HfrEF) is more often seen in conditions with left ventricular dilation. Nevertheless, making pathophysiological distinctions between HFpEF, HFrEF and the relatively novel category of heart failure with mid-range ejection fraction (HfmrEF) are not without problems. This is due to the high number of overlapping comorbidities and risk factors (e.g. hypertension, atherosclerosis, metabolic derangements, infective-immunological factors, etc.) rarely resulting in pure forms of cardiac pathologies.
Our current view on cardiac remodeling links over-activated neuro-humoral pathways (e.g. the renin-angiotensin-aldosterone system and the beta-adrenergic system) to exhaustive levels of cardiomyocyte receptor stimulations, to an aphysiological function of the intracellular signaling cascades, and ultimately to a modified epigenetic control over cardiomyocytes. One of the hurdles of present time cardiology is the difficulty in finding effective medications acting closer to the distal end of the above chain (i.e. cardiomyocyte nuclei) than to the proximal, like current heart failure medications. In this issue, entitled “Cardiac Hypertrophy: from Basic Science to Clinical Application” we present recent advances in the field of cardiac remodeling and its management to foster preclinical and clinical efforts for the preservation of cardiac integrity and function.

Prof. Dr. Zoltán Papp and Dr. Attila Kiss

Guest Editors

 

Manuscript Submission Information

Manuscripts should be submitted online at https://rcm.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reviews in Cardiovascular Medicine is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1950. Submitted papers should be well formatted and use good English.


Keywords

Cardiac hypertrophy; Cardiovascular remodeling; Heart failure; Treatment; Prevention


Share This Special Issue

     


Please wait a minute...
For Selected: Toggle Thumbnails

Current Issue

  • Volume 22, Issue 3